Evidence map›Paper›PMID 41144699›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Reprogramming Tumor-Associated Macrophages via Targeted NAT10 Inhibition to Enhance Colorectal Cancer Immunotherapy.

Jiahao Zhu, Benjie Xu, Rui Hu, Bo Yang, Peipei Shen, Yu Xu, Xiaojun Zhang, Danqi Qian, Gang Wu, Shengjun Ji and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Functional roles and mechanisms of NAT10-mediated RNA acFrontiers in cell and developmental biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jiahao ZhuDepartment of Radiotherapy and Oncology, The Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 214000, P. R. China.
Benjie XuDepartment of Outpatient Chemotherapy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150000, P. R. China.
Rui HuDepartment of Radiotherapy and Oncology, The Affiliated Suzhou Hospital of Nanjing Medical University, Gusu School, Nanjing Medical University, Suzhou, Jiangsu, 215000, P. R. China.
Bo YangDepartment of Radiotherapy and Oncology, The Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 214000, P. R. China.
Peipei ShenDepartment of Radiotherapy and Oncology, The Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 214000, P. R. China.
Yu XuDepartment of Radiotherapy and Oncology, The Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 214000, P. R. China.
Xiaojun ZhangDepartment of Radiotherapy and Oncology, The Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 214000, P. R. China.
Danqi QianDepartment of Radiotherapy and Oncology, The Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 214000, P. R. China.
Gang WuDepartment of Radiotherapy and Oncology, The Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 214000, P. R. China.
Shengjun JiDepartment of Radiotherapy and Oncology, The Affiliated Suzhou Hospital of Nanjing Medical University, Gusu School, Nanjing Medical University, Suzhou, Jiangsu, 215000, P. R. China.
Yutian ZhaoDepartment of Radiotherapy and Oncology, The Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 214000, P. R. China.ORCID https://orcid.org/0000-0001-8003-593X
Ke GuDepartment of Radiotherapy and Oncology, The Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 214000, P. R. China.

Funding

Scientific research project of Wuxi Municipal Health Commission Z202416Supports for Leading Talents in Medical and Health ProfessionWuxi Taihu Lake Talent Plan
6 · The paper itself

Abstract

This study introduces the Sono@NAT10 nanorobot for colorectal cancer (CRC) immunotherapy, designed to target NAT10 condensates in macrophages. Sono@NAT10, enclosed in a macrophage membrane using a metal-organic framework, shows stability under acidic conditions and releases NAT10 siRNA upon ultrasound activation. Flow cytometry and confocal imaging confirm effective macrophage targeting. Sequencing and proteomics reveal that NAT10 regulates SRSF2 protein stability, thereby promoting the transition of macrophages from the M2 to the M1 phenotype. In a CRC mouse model, Sono@NAT10 combined with anti-PD-1 (CD279) antibody inhibited tumor growth and enhances survival. These findings demonstrate the potential of Sono@NAT10 as a novel immunotherapeutic strategy for CRC by modulating NAT10 phase separation, providing a foundation for further exploration of its clinical application.

Indexed as

Colorectal NeoplasmsImmunotherapyTumor-Associated MacrophagesAnimalsCell Line, TumorDisease Models, AnimalHumansMicecolorectal cancer immunotherapymacrophage polarizationNAT10 phase separationsono‐sensitive biomimetic nanorobot targeting NAT10 phase‐separated condensatesSRSF2 AcetylationSRSF2 N4‐acetylcytidine modification

Identifiers

PMID41144699
PMCPMC12786336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.